| Document |
Document Title |
|
WO/2024/153245A1 |
The present invention relates to the technical field of genetic engineering, and relates to two types of compounds for RNA capping and uses thereof. The compound has a structure as represented by formula (I), can be used as an initiating...
|
|
WO/2024/151988A1 |
The sequence-specific fluorescent detection of RNA using a tricyclic cytidine analogue such as DEAtC included as a surrogate for natural cytidine in DNA probe strands and that reports directly on Watson–Crick base pairing. The DEAtC-co...
|
|
WO/2024/123749A9 |
Described are analogues of 3'-ketoriboside having antiviral properties and optionally low toxicity. Generally, these compounds contain a 3'-ketoribose, a lower alkyl attached to the 2'-position of the 3'-ketoribose, a nucleobase or analo...
|
|
WO/2024/139896A1 |
A sugar ring modified nucleoside phosphoramidite monomer, a preparation method therefor and a use thereof. The monomer comprises any one of a compound having a structure as shown in formula (1), a salt of the compound or an isomer of the...
|
|
WO/2024/140624A1 |
Provided herein are lipid compounds that can be used in combination with other lipid components, such as neutral lipids, cholesterol and polymer conjugated lipids, to form lipid nanoparticles for delivery of therapeutic agents (e.g., nuc...
|
|
WO/2024/134541A1 |
The present disclosure relates to certain heterocyclic compounds, including compounds of Formula (I): (I) or pharmaceutically acceptable salts, hydrates, or solvates thereof. The disclosure further relates to the use of the compounds dis...
|
|
WO/2024/135721A1 |
The present invention addresses the problem of providing: a method for producing a production intermediate which is safe and advantageous for industrial production; a production intermediate thereof; and a method for producing a crosslin...
|
|
WO/2024/125604A1 |
The present disclosure relates to diester derivatives of N4-hydroxycytidine (NHC), to pharmaceutical compositions thereof, and to the use and method of the diester derivatives of N4-hydroxycytidine to treat viral infections.
|
|
WO/2024/125595A1 |
Provided are a gemcitabine anti-cancer derivative, the anti-cancer pharmaceutical use thereof, and a preparation method therefor. The compound has the potential to be developed into an anti-cancer drug activated by means of AKR1C3.
|
|
WO/2024/129748A1 |
Provided herein are novel compounds and RNAi agents comprising modified nucleotides, compositions comprising such compounds or RNAi agents, and methods of using such compounds or RNAi agents.
|
|
WO/2024/127214A1 |
The present invention discloses a anticancer activity exhibiting compound of structural formula I : Formula I or a pharmaceutically acceptable salt thereof; in which ▪ W is selected from a group comprising of substituted saturated/unsa...
|
|
WO/2024/129551A1 |
The present disclosure relates to oral dosage forms of pharmaceutical formulations that comprise an antiviral nucleoside, one or more compression aids, one or more glidants, and one or more lubricants, and one or more disintegrants, wher...
|
|
WO/2024/121527A1 |
This invention relates to a novel process for the preparation of 5-fluoro-2'-deoxyuridine-5'-O-[1-naphthyl (benzoxy-L-alaninyl) ] phosphate (NUC-3373) and derivatives thereof. The NUC-3373 made according to this process is more stable th...
|
|
WO/2024/123866A1 |
Embodiments of the present disclosure relate to nucleotide and nucleoside molecules with 3´ vinyl or isonitrile containing blocking groups and/or tetrazine or strained unsaturated ring containing cleavable linkers. Additionally, the pre...
|
|
WO/2024/123206A1 |
The invention relates to chemistry, pharmaceutics and medicine, and more particularly to a method for producing a novel chemical compound which is a derivative of N4-hydroxycytidine and can be used to inhibit the replication of RNA and D...
|
|
WO/2024/123296A1 |
This invention is the use of nicotinamide riboside in the treatment of polycystic ovary syndrome (PCOS) to eliminate the symptoms of PCOS such as ovarian cystic follicle formation, infertility due to anovulation, impaired hormonal balanc...
|
|
WO/2024/123207A1 |
The group of inventions relates to chemistry, pharmaceutics and medicine, and more particularly to a novel chemical compound which is a derivative of N4-hydroxycytidine and can be used to inhibit the replication of RNA and DNA-containing...
|
|
WO/2024/123749A1 |
Described are analogues of 3'-ketoriboside having antiviral properties and optionally low toxicity. Generally, these compounds contain a 3'-ketoribose, a lower alkyl attached to the 2'-position of the 3'-ketoribose, a nucleobase or analo...
|
|
WO/2024/118503A1 |
Embodiments of the present application relate to functionalized N-acetylgalactosamine analogs, methods of making, and uses of the same. In particular, polyvalent N-acetylgalactosamine analogs may be prepared by utilizing a wide variety o...
|
|
WO/2024/114485A1 |
The present invention relates to a fluorescence turn-on nucleoside, a preparation method therefor and a use thereof. The structural formula of the fluorescence turn-on nucleoside is as shown in formula (1). The preparation method can obt...
|
|
WO/2024/112877A1 |
Methods are disclosed for making a targeting ligand-conjugated nucleotide phosphoramidite known as adem-A-GalNAc phosphoramidite, which can be used in the synthesis of oligonucleotides such as therapeutic oligonucleotides.
|
|
WO/2024/112865A1 |
Methods are disclosed for making a 4'-phosphate analog phosphoramidite known as MeMOP, which can be used in the synthesis of oligonucleotides such as therapeutic oligonucleotides.
|
|
WO/2024/107859A1 |
Substituted cyclopentene-oxymethylene phosphonamidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV- K reverse transcriptase activity, and their use in the treatment...
|
|
WO/2024/103979A1 |
The present invention relates to a compound for inhibiting the herpes virus, a preparation method therefor, a pharmaceutical composition comprising the compound, and use of the pharmaceutical in treating or preventing CMV infection disea...
|
|
WO/2024/107850A1 |
Substituted halo-dehydro-3'-deoxyuracil phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase activity, and their use in the treatmen...
|
|
WO/2024/098964A1 |
Provided in the present invention are a vinylphosphonic acid-modified mRNA cap analogue, and a preparation method therefor and the use thereof. The vinylphosphonic acid-modified mRNA cap analogue of the present invention has a more stabl...
|
|
WO/2024/101446A1 |
A compound of the present invention or a salt thereof has a structure represented by formula (I) and has excellent chemical stability. The compound of the present invention is useful, for example, as a material for nucleic acid drugs to ...
|
|
WO/2024/103016A1 |
Substituted 4'-halomethyl-cytidine phosphoramidates and related compounds, pharmaceutical compositions, their use for inhibiting LINE1 reverse transcriptase and/or HERV-K reverse transcriptase activity, and their use in the treatment of ...
|
|
WO/2024/098039A2 |
Extracellular protein degraders and compositions with improved pharmacokinetic properties are provided that have a potent asialoglycoprotein receptor (ASGPR) Binding Ligand bound to an Extracellular Protein Targeting Ligand for the selec...
|
|
WO/2024/097151A1 |
Antibiotic-resistant artificial nucleosides may be used in combination with antibiotics. The artificial nucleosides may be selected from: (I), (II), (III),(IV) wherein R is as defined herein.
|
|
WO/2024/097387A1 |
The present invention provides compounds, compositions, and methods of use thereof for treatment of certain disorders and conditions, for example brain injuries such as stroke or traumatic brain injuries.
|
|
WO/2024/088183A1 |
Provided herein are compounds which exhibit activity in the inhibition of RNA polymerase as well as pharmaceutical compositions comprising these compounds and methods of treatment of viral infections by administration of these compounds ...
|
|
WO/2024/088184A1 |
Provided herein are compounds which exhibit antiviral activity against feline coronavirus and methods of treatment of feline coronavirus infections by administration of these compounds or the pharmaceutical compositions comprising the same.
|
|
WO/2024/083746A1 |
The invention pertains to methods for the synthesis of oligonucleotides using pseudo solid-phase protecting groups, wherein said method comprises at least one aqueous extraction carried out in the presence of one or more amide solvents S...
|
|
WO/2024/084025A1 |
The invention pertains to a method for producing a plant cell comprising a modified RNA molecule, comprising the steps of i) providing the plant cell; and ii) introducing the modified RNA molecule into the plant cell. The modified RNA mo...
|
|
WO/2024/086592A2 |
Disclosed are halogen containing nucleotide and nucleoside therapeutic compositions and uses related thereto. In certain embodiments, the disclosure relates to the treatment or prophylaxis of viral infections. Such viral infections can i...
|
|
WO/2024/086312A1 |
The present disclosure provides enhanced nicotinamide adenine dinucleotide (NAD+) compositions and pharmaceutical formulations, useful in the treatment of disorders and diseases regulated by deficiencies in NAD+, and methods of preparati...
|
|
WO/2024/081308A1 |
The present disclosure discloses compositions comprising maribavir, methods of providing the same, and compositions providing intermediates useful in providing maribavir.
|
|
WO/2024/077410A1 |
The present application relates to the technical field of metal ion chemistry, and provides a method for reducing an azide methoxy group, a sequencing method, and a kit. The method for reducing an azide methoxy group provided by the pres...
|
|
WO/2024/076951A2 |
The application provides compounds of Formula (I) as further defined herein, pharmaceutical compositions comprising said compounds, and methods of using said compounds and compositions for the treatment and/or prevention of various viral...
|
|
WO/2024/076915A1 |
Compounds, compositions, and methods useful for treating a viral infection, such as human immunodeficiency virus (HIV) infection, are disclosed. In particular, 4'-thionucleoside analogues and methods for their preparation and use as ther...
|
|
WO/2024/064701A2 |
The disclosure provides adenosine analogs for the treatment of disease such as pain and inflammatory conditions.
|
|
WO/2024/062413A1 |
The present disclosure includes oligonucleotides and nucleic acid compositions having stabilized phosphate moieties. Formula (Ia) and Formula (Ib), wherein: X is selected from a 3- to 5-membered cycloalkyl, -CHCH-, a 3- to 5-membered het...
|
|
WO/2024/059609A1 |
The present disclosure relates to pharmaceutical forms of a CD73 inhibitor, polymorphic forms of the pharmaceutical forms, pharmaceutical compositions comprising the pharmaceutical forms, and methods of treating subjects having cancer by...
|
|
WO/2024/059703A1 |
Provided herein are engineered terminal deoxynucleotidyl transferase (TdT) proteins with certain modifications, including mutations to confer thermal stability and to install an exposed amino acid residue to which a small molecule can be...
|
|
WO/2024/055758A1 |
The present invention relates to the technical field of biological medicines. Disclosed are a cyclic dinucleotide metal compound, and a preparation method therefor and a use thereof. The structural formula of the compound is [M(cyclic di...
|
|
WO/2024/059258A1 |
Click-labeled uridine bases, nucleosides, and phosphoramidites are provided, including improved methods of synthesis, oligonucleotides comprising the click-labeled nucleosides, methods of synthesizing spin-labeled oligonucleotides using ...
|
|
WO/2024/054997A1 |
Provided herein are methods to treat rhegmatogenous retinal detachment (RRD) and/or improve visual outcomes of RRD.
|
|
WO/2024/051696A1 |
The present invention relates to a compound for RNA capping and use thereof and belongs to the technical field of genetic engineering. The compound has a structure represented by formula I. The compound is used for capping an mRNA5' end,...
|
|
WO/2024/050267A1 |
The present disclosure is directed to oligonucleotide dendrons comprising an oligonucleotide stem linked to one or more oligonucleotide branches. The disclosure also provides methods of using the oligonucleotide dendrons.
|
